Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Presentation of Phase 1 Clinical Data of MDX-1100 at Digestive Disease Week
2008
PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX)
announced today that it has initiated the Phase 2 clinical development program of
MDX-1100, a fully human monoclonal antibody that targets CXCL10 (also known as
IP-10), in ulcerative colitis (UC) and rheumatoid arthritis (RA). MDX-1100 could
potentially treat UC and RA by suppressing the inflammatory process characteristic
of these diseases.
"Based on positive safety data in Phase 1 studies, we have initiated patient
enrollment in Phase 2 studies that are designed to establish proof-of-concept," said
Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at
Medarex. "We are optimistic about the broad potential of MDX-1100 to address a
range of inflammatory diseases."
Patients in the Phase 2 randomized, double-blind, placebo-controlled,
multi-center study in UC will be administered MDX-1100 at 10 mg/kg or placebo every
2 weeks for a total of 4 doses. All patients will have active UC and will continue
standard UC therapy during the trial. The trial is expected to enroll 106 patients
at multiple sites internationally. The primary endpoint of the study is the
response rate at 8 weeks. Clinical response is based on the Mayo score, a composite
endpoint that assesses stool frequency and the amount of bloody stool per day as
recorded in a patient diary, physician global assessment and the assessment of colon
mucosal inflammation ascertained by endoscopy.
Patients in the Phase 2 randomized, double-blind, placebo-controlled,
multi-center study in RA will be administered MDX-1100 at 10 mg/kg or placebo every
2 weeks for a total of 6 doses. All patients will have active RA while on
methotrexate. The trial is expected to enroll 70 patients at multiple sites in
Europe. The primary endpoint of the study is the ACR20 response, a composite
endpoint that indicates a 20% improvement in RA signs and symptoms, at 12 weeks.
Medarex also announced that results from the MDX-1100 Phase 1 trials will be
presented at the Digestive Disease Week (DDW) meeting, being held May 17 - 22, 2008
in San Diego. The following abstracts are expected to be the subject of
presentations at the DDW 2008 conference:
-- "A Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and
Pharmacokinetic Study of MDX-1100, a Fully Human Anti-CXCL10 Monoclonal
Antibody, in Healthy Subjects" (Abstract #T1145) - Poster presentation
on May 20, 2008 from 12:00 to 2:00 PM CDT.
-- "A Phase 1 Open-Label, Single-Dose, Dose-Escalation Study of MDX-1100,
a High-Affinity, Neutralizing, Fully Human IgG1k Anti-CXCL10 (IP10)
Monoclonal Antibody, in Ulcerative Colitis" (Abstract #704) - Oral
presentation on May 20, 2008 from 3:00 to 3:15 PM CDT.
-- "CXCL10 Expression and Biological Activities in Inflammatory Bowel
Disease" (Abstract #W1170) - Poster presentation on May 21, 2008 from
12:00 to 2:00 PM CDT.
These presentations support the development of MDX-1100 for the treatment of
inflammatory diseases such as ulcerative colitis and rheumatoid arthritis.
About MDX-1100
MDX-1100 is a fully human antibody that targets CXCL10 (also known as IP-10), a
chemokine expressed in association with multiple inflammatory disease indications
such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.
About Ulcerative Colitis
Ulcerative colitis (UC) is a chronic inflammatory bowel disease of the colon and
is characterized by inflammation and ulceration of the lining of the colon. Symptoms
typically include bloody diarrhea and abdominal pain and in severe cases may require
colectomy. According to the Crohn's & Colitis Foundation of America, it is
estimated that there are up to approximately 500,000 Americans with ulcerative
colitis.
About Rheumatoid Arthritis
According to the American College of Rheumatology, more than two million
Americans suffer from rheumatoid arthritis (RA), a chronic autoimmune disease that
develops when certain cells of the immune system inappropriately attack healthy
joint tissue, thereby causing swelling, inflammation and damage of joints, as well
as systemic inflammation and damage of other tissues.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and
potential commercialization of fully human antibody-based therapeutics to treat
life-threatening and debilitating diseases, including cancer, inflammation,
autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R)
technology and product development and clinical manufacturing experience to
generate, support and potentially commercialize a broad range of fully human
antibody product candidates for itself and its partners. Over forty of these
therapeutic product candidates derived from Medarex technology are in human clinical
testing or have had INDs submitted for such trials, with seven of the most advanced
product candidates currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building value by
developing a diverse pipeline of antibody products to address the world's unmet
healthcare needs. For more information about Medarex, visit its website at
www.medarex.com.
Medarex Statement on Cautionary Factors
Except for the historical information presented herein, matters discussed herein
relating to the development of MDX-1100 constitute forward-looking statements, as
defined by the Private Securities Litigation Reform Act of 1995, that are subject to
certain risks and uncertainties that could cause actual results to differ materially
from any future results, performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including statements preceded
by, followed by, or that include the words "preliminary"; "potential"; "may"; or
similar statements are forward-looking statements. Medarex disclaims, however, any
intent or obligation to update these forward-looking statements. Risks and
uncertainties include risks associated with the development of MDX-1100, unforeseen
safety issues resulting from the administration of antibody products in humans, as
well as risks detailed from time to time in Medarex's public disclosure filings with
the U.S. Securities and Exchange Commission (SEC), including its Annual Report on
Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on
Form 10-Q. There can be no assurance that such product development efforts will
succeed, or whether other developed products will receive required regulatory
clearance or that, even if such regulatory clearance were received, such products
would ultimately achieve commercial success. Copies of Medarex's public disclosure
filings are available from its investor relations department.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of
Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
-0- 05/12/2008
/CONTACT: Laura S. Choi, Investor Relations of Medarex, Inc., +1-609-430-2880,
x2216, or media, Nichol Harber of Corporate Communications, +1-609-430-2880, x2214/
/Company News On-Call: http://www.prnewswire.com/comp/108265.html/
/Web site: http://www.medarex.com /
(MEDX)
CO: Medarex, Inc.; Digestive Disease Week 2008 ST: New Jersey IN: HEA MTC BIO SU:
TRI
RF-LL -- NEM033 -- 2805 05/12/2008 08:00 EDT http://www.prnewswire.com
©2001-2008 Medarex, Inc. All rights reserved.